SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 13.21 |
| Enterprise Value ($M) | n/a |
| Book Value ($M) | 32.85 |
| Book Value / Share | 1.14 |
| Price / Book | n/a |
| NCAV ($M) | -15.43 |
| NCAV / Share | -0.54 |
| Price / NCAV | n/a |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.57 |
| Return on Assets (ROA) | -0.37 |
| Return on Equity (ROE) | -0.53 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 0.82 |
| Current Ratio | 0.99 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 11.02 |
| Assets | 59.30 |
| Liabilities | 26.45 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 24.52 |
| Operating Income | -14.09 |
| Net Income | -27.18 |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | -4.25 |
| Cash from Investing | -1.56 |
| Cash from Financing | 1.02 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Ingalls & Snyder Llc | 5.01 | 25.13 | |
| 13G/A | Charmquark TWEE | 6.28 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 43,075 | 190,423 | 22.62 | |
| 100,239 | 337,304 | 29.72 | |
| 448,766 | 1,576,560 | 28.46 | |
| 57,471 | 319,679 | 17.98 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| IMRX – Immuneering Corporation | INAB – IN8bio, Inc. |
| IOVA – Iovance Biotherapeutics, Inc. | IRON – Disc Medicine, Inc. |
| ITOS – iTeos Therapeutics, Inc. |
Financial data and stock pages provided by
Fintel.io